Biocryst Pharmaceuticals reported $-42520000 in Net Income for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
DBV Technologies DBVT:US USD -17287000 5.75M
Alnylam Pharmaceuticals ALNY:US USD -405920000 128.52M
Biocryst Pharmaceuticals BCRX:US USD -42520000 16.34M
Chugai Pharma 4519:JP JPY 67.8B 4.58B
Daiichi Sankyo 4568:JP JPY 39.46B 20.6B
Enanta Pharmaceuticals ENTA:US USD -26348000 5.35M
Gilead Sciences GILD:US USD 1.79B 645M
GlaxoSmithKline GSK:LN GBP 10.32B 9.48B
Glaxosmithkline GSK:US GBP 10.32B 9.48B
Intra Cellular Therapies ITCI:US USD -53508000 33.1M
IONIS PHARMACEUT IONS:US USD -46992000 58.14M
Karyopharm Therapeutics KPTI:US USD -36324000 12.74M
Mirati Therapeutics MRTX:US USD -173561000 2.88M
Neurocrine Biosciences NBIX:US USD 68.5M 85.4M
Ptc Therapeutics PTCT:US USD -109315000 42.77M
Regeneron Pharmaceuticals REGN:US USD 1.32B 463.6M
Sarepta Therapeutics SRPT:US USD -257738000 26.26M
Ultragenyx Pharmaceutical RARE:US USD -245106000 86.94M
Vertex Pharmaceuticals VRTX:US USD 930.5M 120M
YTE INCY:US USD 112.78M 48.66M